Presented Phase 1b data at the 2026 Multidisciplinary Head and Neck Cancers Symposium (MHNCS) showing that ﬁcerafusp alfa 2000mg Q2W plus pembrolizumab was generally well‑tolerated and produced rapid, deep, and durable responses.

ficerafusp alfa (BCA101) - Bicara Therapeutics

Mar 30, 2026